Abstract
Ovarian cancer is the fifth most common cause of death due to cancer in women despite being the tenth in incidence. Unfortunately, the five-year survival rate is only 45%, which has not improved much in the past 30 years. Even though the majority of women have successful initial therapy, the low rate of survival is due to the eventual recurrence and succumbing to their disease. With the recent release of the Cancer Genome Atlas for ovarian cancer, it was shown that the PI3K/AKT/mTOR pathway was one of the most frequently mutated or altered pathways in patients’ tumors. Researching how the PI3K/AKT/mTOR pathway affects the progression and tumorigensis of ovarian cancer will hopefully lead to new therapies that will increase survival for women. This review focuses on recent research on the PI3K/AKT/mTOR pathway and its role in the progression and tumorigensis of ovarian cancer.
Highlights
Ovarian cancer is the fifth most common cause of death due to cancer in women, despite ranking tenth in incidence [1]
The PI3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a central regulator in both normal cell physiology and in cancer proliferation, tumorigenesis, and metastasis
PI3K/AKT/mTOR pathway has demonstrated to play a key role in ovarian cancer tumorigenesis, progression, and chemotherapy resistance
Summary
Ovarian cancer is the fifth most common cause of death due to cancer in women, despite ranking tenth in incidence [1]. The PI3K/Akt/mTOR pathway is a central regulator in both normal cell physiology and in cancer proliferation, tumorigenesis, and metastasis. The PI3K/Akt/mTOR pathway has a key role in promoting cell survival in the normal ovary. PI3K/AKT/mTOR pathway has demonstrated to play a key role in ovarian cancer tumorigenesis, progression, and chemotherapy resistance.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
